MML Investors Services LLC Cuts Stock Holdings in Altimmune, Inc. (NASDAQ:ALT)

MML Investors Services LLC lowered its stake in Altimmune, Inc. (NASDAQ:ALT) by 27.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,450 shares of the company’s stock after selling 13,259 shares during the period. MML Investors Services LLC’s holdings in Altimmune were worth $212,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Larson Financial Group LLC bought a new position in shares of Altimmune during the third quarter valued at about $31,000. PFG Investments LLC purchased a new stake in Altimmune in the 2nd quarter worth approximately $67,000. Principal Financial Group Inc. bought a new stake in shares of Altimmune in the 2nd quarter worth approximately $70,000. Verus Capital Partners LLC purchased a new position in shares of Altimmune during the second quarter valued at approximately $82,000. Finally, XTX Topco Ltd purchased a new position in shares of Altimmune during the second quarter valued at approximately $96,000. Institutional investors own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

ALT has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research report on Thursday, November 14th. UBS Group began coverage on shares of Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Stock Performance

Shares of Altimmune stock opened at $8.00 on Friday. The company has a 50-day simple moving average of $8.00 and a two-hundred day simple moving average of $7.12. The stock has a market capitalization of $569 million, a PE ratio of -5.16 and a beta of 0.15. Altimmune, Inc. has a 52-week low of $5.28 and a 52-week high of $14.84.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the previous year, the business posted ($0.39) earnings per share. As a group, equities research analysts forecast that Altimmune, Inc. will post -1.36 EPS for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.